跳至主要内容
临床试验/NCT04666324
NCT04666324Unknown不适用

Effects of Simethicone and Multilac Baby on Fecal Calprotectin Levels Infantile Colic

The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2020年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
100
试验地点
2
主要终点
Change of days of crying

研究概览

简要总结

Open trial with two parallel arms, assessing the effects of Simethicone and Multilac Baby on crying behavior and fecal calprotectin levels in babies diagnosed for infantile colic.

详细描述

Babies aged 3 to 6 weeks will be diagnosed for infantile colic using the Wessel's criteria. Study design will be open label with two parallel arms (Simethicone and Multilac Baby). Multilac Baby is a synbiotic product containing probiotic bacteria (six lactobacilli and 3 bifidobacteria). Effects of treatments on crying behavior will be assessed by using parental 24h paper diaries. Fecal calprotectin values at the beginning and at the end of the study will be evaluated using BÜHLMANN Quantum Blue® Calprotectin High Range (Schönenbuch, Switzerland), a quantitative immunoassay.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
3 Weeks 至 6 Weeks(Child)
性别
All
接受健康志愿者

入选标准

  • diagnosed for infantile colic according to Wessel's criteria

排除标准

  • previous treatment with probiotic or synbiotic
  • previous treatment with antibiotics

研究组 & 干预措施

Simethicone Solution

Active Comparator

Treatment with simethicone (Espumisan®, 100 mg/ml, Berlin-Chemie / Menarini Polska Sp z o.o., Warsaw, Poland) for four weeks. Simethicone was administered 3-6 times per day with each treatment comprising 6 drops of the 100 mg/ml emulsion.

干预措施: Simethicone Solution (Drug)

Multilac Baby

Experimental

Treatment with one stick pack of the multi-strain synbiotic (Multilac® Baby, Vivatrex GmbH, Aachen, Germany) per day for four weeks. Each stick pack of Multilac® Baby contains a total of 10^9 colony forming units (CFU) with equal CFU amounts of the following probiotic bacteria: L. acidophilus LA-14, L. casei R0215; L. paracasei Lpc-3; L. plantarum Lp-115; L. rhamnosus GG, L. salivarius Ls-33, B. lactis Bl-04, B. bifidum R0071, B. longum R0175 and 1.43 g of the prebiotic fructooligosaccharides.

干预措施: Multilac Baby (Dietary Supplement)

结局指标

主要结局

Change of days of crying

时间窗: Three weeks

Measurement of days of crying during last three weeks before enrollment and before the end of treatment. Treatment success will be determined by calculation the percentage of patients for whom the measurement will be reduced by the respective treatment by equal or more than 50 percent, compared to the value at the time of enrollment.

Change of average duration of evening crying

时间窗: Three weeks

Measurement of average duration of evening crying during last three weeks before enrollment and before the end of treatment. Treatment success will be determined by calculation the percentage of patients for whom the measurement will be reduced by the respective treatment by equal or more than 50 percent, compared to the value at the time of enrollment.

Change of fecal calprotectin values

时间窗: 1-30 days

BÜHLMANN Quantum Blue® Calprotectin High Range (Schönenbuch, Switzerland). It is a quantitative determination of fecal calprotectin through a sandwich immunoassay. Treatment success will be determined by calculation the percentage of patients for whom the measurement will be reduced by the respective treatment by equal or more than 50 percent, compared to the value at the time of enrollment.

次要结局

未报告次要终点

研究者

发起方
The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验